0000899243-17-026011.txt : 20171113
0000899243-17-026011.hdr.sgml : 20171113
20171113160543
ACCESSION NUMBER: 0000899243-17-026011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171108
FILED AS OF DATE: 20171113
DATE AS OF CHANGE: 20171113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SNYDERMAN RALPH
CENTRAL INDEX KEY: 0001178031
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36536
FILM NUMBER: 171195843
MAIL ADDRESS:
STREET 1: C/O SAIC
STREET 2: 10260 CAMPUS POINT DR M/S F3
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CareDx, Inc.
CENTRAL INDEX KEY: 0001217234
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 943316839
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3260 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 415-287-2300
MAIL ADDRESS:
STREET 1: 3260 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: XDx, Inc.
DATE OF NAME CHANGE: 20071010
FORMER COMPANY:
FORMER CONFORMED NAME: EXPRESSION DIAGNOSTICS INC
DATE OF NAME CHANGE: 20030203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-08
0
0001217234
CareDx, Inc.
CDNA
0001178031
SNYDERMAN RALPH
C/O CAREDX, INC.
3260 BAYSHORE BOULEVARD
BRISBANE
CA
94005
1
0
0
0
Option to Purchase Common Stock
12.40
2017-11-08
4
D
0
10948
D
2024-06-19
Common Stock
10948
0
D
Option to Purchase Common Stock
5.49
2017-11-09
4
A
0
6679
A
2024-11-09
Common Stock
6679
6679
D
The shares underlying the cancelled option were vested and immediately exercisable.
On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares.
Represents a stock option granted pursuant to the Exchange Offer (the "New Options").
The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017.
The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer,
(Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.
/s/ Peter Maag as attorney-in-fact for Ralph Snyderman
2017-11-10